Interferon-γ and Interleukin-10 Gene Polymorphisms are not Predictors of Chronic Hepatitis C (Genotype-4) Disease Progression

Nermine Ahmed Bahgat¹, Manal Mohamed Kamal¹, Ashraf Omar Abdelaziz², Mohamed Ahmed Mohye², Hend Ibrahim Shousha²*, Mae Mohamed Ahmed¹, Tamer Mahmoud Elbaz², Mohamed Mahmoud Nabil²

Abstract

Immunoregulatory cytokines have an influence on hepatitis C virus (HCV) infection outcome. This study aimed to determine whether single nucleotide polymorphisms (SNP) in IFN-γ and IL-10 genes are associated with susceptibility and/or are markers of prognosis regarding chronic hepatitis C outcomes. IFN-γ (+874T/A) and IL-10 (-1082G/A) genotypes were determined in 75 HCV genotype 4 patients with different disease severities (chronic hepatitis, n=25, liver cirrhosis and hepatocellular carcinoma (HCC) on top of liver cirrhosis, n=50) and 25 healthy participants using allele-specific polymerase chain reaction. No statistical differences in allele or genotype distributions of IFN-γ and IL-10 genes were detected between patients and controls or between patient groups. No significant difference in the frequency of IL-10 SNP at position -1082 or IFN-γ at position +874T/A was found between chronic HCV genotype 4 and with progression of disease severity in liver cirrhosis or HCC. In conclusion; interferon-γ and interleukin-10 gene polymorphisms are not predictors of disease progression in patients with chronic hepatitis C (Genotype-4).

Keywords: Chronic hepatitis C - single nucleotide polymorphism - IFN-γ - IL-10 - HCV genotype 4

Asian Pac J Cancer Prev, 16 (12), 5025-5030

Introduction

Hepatitis C virus (HCV) is a major cause of a wide spectrum of liver diseases ranging from chronic hepatitis to cirrhosis and hepatocellular carcinoma (HCC). It infects almost 3% of the world’s population. Egypt has the highest prevalence of HCV worldwide (15%) with genotype-4a accounting for almost 90% of infections (Guerra et al., 2012). Egypt has an estimated annual incidence of HCV about 150,000 cases (Galal et al., 2014).

The natural history of HCV is quite variable. In the majority of cases, neither the early innate immune response nor the adaptive immunity clears the virus and the infection becomes chronic. The ineffective inflammatory response drives fibrogenesis and the development of cirrhosis (Heydtmann et al., 2009). Factors promoting disease progression include: duration of infection, age at the time of infection, gender, alcohol consumption, immunosuppression (e.g. HIV co-infection or organ transplantation), obesity, insulin resistance, co-infection with other viruses and genetic factors (Al-Kubaisy et al., 2014). Once patients develop cirrhosis, HCC develops at approximately 1-4% per year and is increased in patients with raised α-fetoprotein levels at baseline (Asahina et al., 2013). Cytokines form a regulatory network to directly or indirectly stimulate downstream signaling pathways in the occurrence of malignancies (Duan et al., 2014). In addition to chronic inflammation and immune-mediated destruction of liver cells; also oxidative stress, apoptosis induced by HCV, DNA damage cause genomic aberrations and continuous hepatic regeneration that promotes HCC development within the HCV infected patients (Zekri et al., 2014).

CD4+T helper cell type 1 (Th1) and type 2 (Th2) cytokines are the principal coordinators of the adaptive immune response against HCV via secreting antiviral cytokines and activating viral specific B cells and CD8+T cells (Kaplan et al., 2007). The TH1 subtype is characterized by a cell-mediated immune response evoked by TH1- cytokines (IL-2, IL-12 and IFN-γ) and the TH2 subtype promotes a strong humoral response under the control of TH2-associated cytokines (IL-4, IL-6 and IL-10) (Grakoui et al., 2003). Accordingly, it is supposed that the genetic variations affecting cytokine expression might influence chronic hepatitis C outcomes (Ollier, 2004). One

¹Clinical and Chemical Pathology Department, Faculty of medicine, Cairo University; ²Endemic medicine and Hepatogastroenterology Department, Faculty of Medicine, Cairo University, Egypt  *For correspondence: hendshousha@yahoo.com

DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.5025

IFN-γ and IL-10 Polymorphisms Do Not Predict HCV-G4 Disease Progression
of the most important Th1 cytokines is IFN-γ. Significant correlation was observed between expression level of IFN-γ mRNA and stage of fibrosis in chronic hepatitis C (Gigi et al., 2008); its level may interfere and affect the outcome of antiviral therapy (Sarvari et al., 2014). It has been established that the T-to-A polymorphism at position +874 of the first intron of IFN-γ gene could directly influence IFN-γ production level (Bouzgarrou et al., 2009). It was also concluded that heterogeneity at +2109 locus of IFN-γ gene but not at +874 locus could interfere with successful therapy in patients infected with HCV genotype 1 (Sarvari et al., 2014).

Interleukin-10 (IL-10) is an immunoregulatory cytokine produced by Th2 cells, macrophages and regulatory T-cells. It is also produced by various cells in the liver including hepatocytes, sinusoidal endothelial cells, Kupffer cells, stellate cells, and liver-associated lymphocytes. It has anti-inflammatory activity by inhibiting the synthesis of cytokines such as IL-6, IL-8, IL-12, and TNF-α by activated macrophage and IFN-γ by T cells. Its expression is downregulated in chronic HCV and may influence HCV infection susceptibility as well as spontaneous and treatment-induced viral eradication (Helal et al., 2014). The IL-10 promoter is highly polymorphic, and three SNPs -1082G/A, -819C/T, -592C/A were associated with differential IL-10 expression (Bouzgarrou et al., 2009). This study aims to investigate whether single nucleotide polymorphisms in IFN-γ and IL-10 genes are associated with susceptibility and/or are markers of prognosis to chronic hepatitis C outcomes.

Materials and Methods

This study was conducted on 75 HCV related chronic liver disease Egyptian patients from May 2012 to March 2014. Patients were assigned into: group I including 25 patients with chronic hepatitis C who were recruited from Endemic Medicine Department, school of medicine, Cairo University. All patients did not receive prior antiviral therapy. Group II including 50 patients: 25 HCC patients attending the multidisciplinary HCC clinic, Faculty of medicine, Cairo University who did not receive prior therapy for HCC in addition to 25 patients with HCV related liver cirrhosis that were also recruited from Endemic Medicine Department, school of medicine, Cairo University. Group III included 25 participants were selected randomly from healthy blood donors and enrolled as a control group. They were seronegative for HCV and HBV.

HCC was diagnosed according to the American Association for the Study of Liver Diseases (AASLD) updated practice guidelines (Bruix et al., 2011). Patients and controls were gender and age matched, and they were from the same geographical area. Approval for the study was given by the National Ethical Committee of Cairo University. All patients were subjected to full history taking and clinical examination. The following investigations had been done: Complete liver & kidney functions, Coagulation profile (Prothrombin Time& Concentration) and complete blood picture. HCV antibodies by 3rd generation enzyme linked immunosorobant assay. HCV genotyping was done using reverse transcription polymerase chain reaction (RT-PCR) on applied biosystems TR Step One Real Time PCR system.

**DNA extraction**

Peripheral blood (5 ml) was collected in ethylenediaminetetraacetic acid (EDTA) tubes. Genomic DNA was extracted from peripheral leukocytes using the standard method (salting out procedure) (Miller et al., 1988) and stored at -20°C. Blood cells were mixed with Triton lysis buffer (0.32 mol/l sucrose, 1% Triton X-100, 5 mmol/l MgCl2, 10 mmol/l Tris-HCl, pH 7.5). Leukocytes were spun down and washed with sterilized H2O. The pellet was incubated with proteinase K at 56°C and subsequently salted out at 4°C using a 5-mol/l NaCl solution. Precipitated proteins were removed by centrifugation. DNA in the supernatant was precipitated with ethanol. The DNA pellet was dissolved in 400 µl sterilized H2O and stored at -20°C until use.

IFN-γ (+874 T/A) and IL-10 (-1082 G/A) genotyping: Genotyping for polymorphism in IFN-γ (+874 T/A) and IL-10 (-1082 G/A) was carried out by the allele-specific PCR (AS-PCR) assay. For the genotyping of IFN-γ (+874 T/A), three primers described by Pravica et al. were used (Pravica et al., 2000): 5’ primers specific for IFN-γ +874T (5’-TCTCTAACAACAAATCAAAT-3') or IFN-γ +874A (5’-TCTCTAACAACAAATCAAAT-3'), were separately mixed to a 3’ common anti-sense primer (5’-TCAAACAAAGCTGTACATCACA-3') under the following conditions: the reaction mixture was containing 5 µl of genomic DNA, 5.5 µl distilled water, 12.5 µl master mix (TaqDNAq polymerase, buffer and MgCl2), 1 µl sense primer and 1 µl common anti-sense primer. Two samples are available for each participant, one for each specific T or A allele of IFN-γ.

Amplification was performed using the thermal cycler (BiomeraTE-3000, Germany) according to the following protocol: one cycle of 95°C for 1 minute followed by 10 cycles of 95°C for 15 seconds, 62°C for 50 seconds, and 72°C for 40 seconds, then 20 cycles of 95°C for 20 seconds, 56°C for 50 seconds and 72°C for 50 seconds. Similarly, primers described by Mullighan et al. were used to detect the G-to-A transition polymorphism at position -1082 of IL-10 gene (Mullighan et al., 1999). The specific primer sequences used were as follows: the 3’ common anti-sense primer 5’-CAGTGCCAACCTGAAATTTGGG-3’; the IL-10-1082G: 5’CTACTAAGGCTTTCTTGGG-3’; the IL-10-1082A: 5’ACTACTANAGGCTTTGGGAA-3’. All reactions were performed in a reaction mixture of 25 µl volume containing 5 µl of genomic DNA, 5.5 µl distilled water, 12.5 µl master mix (TaqDNAq polymerase, buffer and MgCl2), 1 µl sense primer and 1 µl common anti-sense primer. Two samples are available for each participant, one for each specific G or A allele of IL-10. Reaction conditions were as follows: 95°C for 3 minutes followed by 35 cycles.
at: 95°C for 45 seconds, 58°C for 40 seconds, 72°C for 1 minute with final extension at 72°C for 7 minutes. The amplified products were separated by electrophoresis on a 1% agarose gel stained with ethidium bromide. The gel was visualized under an ultraviolet trans-illuminator with a 100-base pair (bp) ladder (SIGMA chemical Co., Cairo, Egypt) and photographed.

Statistical analysis
The allele frequencies were tested for the Hardy-Weinberg equilibrium. The same test was used to evaluate any significant differences in the IFN-γ and IL-10 allele/genotype frequencies between patients and controls and among subgroups of patients (chronic hepatitis vs. LC/HCC). Values of p<0.05 were considered statistically significant. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the relative disease risk conferred by a specific allele or genotype. Genotype frequencies between patients and controls and any significant differences in the IFN-γ and IL-10 allele/genotype frequencies were compared among the groups by multivariate logistic regression analysis. Data were analyzed using the EpiInfo statistical program (version 5.01a-1991; Centers for Disease Control and Epidemiology Program office, Atlanta, GA). Multivariate analysis was made using SPSS 13.0 software (SPSS Inc., Chicago, IL).

Results
Our patients were divided according to the presence or absence of liver cirrhosis. The clinical and laboratory data of the different studied groups are shown in Table 1. Some statistical differences were observed between patients and controls in regard to age, bilirubin, albumin, AST, ALT, Hb and platelet count by univariate analysis.

IFN-γ (+874 T/A) and IL-10 (-1082 G/A) allelic and genotypic distribution
IFN-γ and IL-10 allele and genotype frequencies in all samples are shown in Table 2. Genotype distributions in control subjects were consistent with Hardy-Weinberg equilibrium. No statistically significant differences were detected between patients and controls for both polymorphisms.

Genotype frequency analysis of IFN-γ at position +874 between chronic hepatitis patients and LC/HCC; representing the progressing disease severity; showed a higher rate of TT, TA, AA and TT+TA genotypes in LC/HCC group than in chronic hepatitis although not statistically significant (Table 2). In addition, the IFN-γ 874T allele was found to be more frequent in patients with end-stage HCV than in patients with chronic hepatitis.

Table 1. Demographic, Clinical and Virological Factors of the Studied Population

<table>
<thead>
<tr>
<th></th>
<th>HCV (n=25)</th>
<th>LC/HCC (n=50)</th>
<th>Control (n=25)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>sex Male</td>
<td>17 (0.68)</td>
<td>41 (0.84)</td>
<td>18 (0.72)</td>
<td>0.67 (NS)</td>
</tr>
<tr>
<td>Female</td>
<td>6 (0.32)</td>
<td>9 (0.16)</td>
<td>7 (0.28)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>46.32 ± 4.66</td>
<td>52.30 ± 4.41</td>
<td>44.60 ± 5.18</td>
<td>0.008</td>
</tr>
<tr>
<td>T.Bil.</td>
<td>0.74 ± 0.11</td>
<td>2.35 ± 0.21</td>
<td>0.83 ± 0.13</td>
<td>0.006</td>
</tr>
<tr>
<td>Albumin</td>
<td>4.38 ± 0.37</td>
<td>2.81 ± 0.83</td>
<td>3.86 ± 1.15</td>
<td>0.009</td>
</tr>
<tr>
<td>AST</td>
<td>61.88 ± 64.29</td>
<td>75.64 ± 32.93</td>
<td>21.40 ± 5.33</td>
<td>0.008</td>
</tr>
<tr>
<td>ALT</td>
<td>68.20 ± 59.26</td>
<td>48.08 ± 22.34</td>
<td>22.56 ± 8.53</td>
<td>0.007</td>
</tr>
<tr>
<td>Hb</td>
<td>14.20 ± 1.46</td>
<td>11.02 ± 2.02</td>
<td>11.89 ± 0.89</td>
<td>0.008</td>
</tr>
<tr>
<td>TLC</td>
<td>9.37 ± 11.62</td>
<td>4.53 ± 2.38</td>
<td>4.93 ± 0.65</td>
<td>0.05 (NS)</td>
</tr>
<tr>
<td>Platelets</td>
<td>208.56 ± 59.18</td>
<td>117.52 ± 66.34</td>
<td>210.88 ± 49.18</td>
<td>0.006</td>
</tr>
</tbody>
</table>

Table 2. Differential Distribution of the IFN and IL10 Genotypes in Healthy Controls and Hepatitis C Virus (HCV) Patients at Different Stages of Chronic HCV Infection

<table>
<thead>
<tr>
<th>Genotype IFN</th>
<th>Control (n=25)</th>
<th>Patients (n=75)</th>
<th>OR(95%CI)</th>
<th>P*</th>
<th>Chronic hepatitis (n=25)</th>
<th>LC/HCC (n=50)</th>
<th>OR(95% CI)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>TT</td>
<td>4 (0.16)</td>
<td>21 (0.28)</td>
<td>1.97(0.47-8.2)</td>
<td>0.35</td>
<td>5 (0.20)</td>
<td>16 (0.32)</td>
<td>1.92 (0.46-8)</td>
<td>0.37</td>
</tr>
<tr>
<td>TA</td>
<td>15 (0.60)</td>
<td>38 (0.51)</td>
<td>0.95 (0.3-2.9)</td>
<td>0.92</td>
<td>14 (0.56)</td>
<td>24 (0.48)</td>
<td>1 (0.31-3.44)</td>
<td>1</td>
</tr>
<tr>
<td>AA</td>
<td>6 (0.24)</td>
<td>16 (0.21)</td>
<td>1</td>
<td>--</td>
<td>6 (0.24)</td>
<td>10 (0.20)</td>
<td>1</td>
<td>--</td>
</tr>
<tr>
<td>TT+TA</td>
<td>19 (0.40)</td>
<td>59 (0.79)</td>
<td>1.2 (0.4-3.4)</td>
<td>0.77</td>
<td>19 (0.76)</td>
<td>40 (0.80)</td>
<td>1.26 (0.4-3.99)</td>
<td>0.69</td>
</tr>
<tr>
<td>Allele</td>
<td>T</td>
<td>23</td>
<td>80</td>
<td>1.3(0.71-2.55)</td>
<td>0.37</td>
<td>24</td>
<td>56</td>
<td>1.38 (0.70-2.72)</td>
</tr>
<tr>
<td>A</td>
<td>27</td>
<td>70</td>
<td>1</td>
<td>--</td>
<td>26</td>
<td>44</td>
<td>1</td>
<td>--</td>
</tr>
<tr>
<td>Genotype IL-10</td>
<td>G</td>
<td>4 (0.16)</td>
<td>15 (0.20)</td>
<td>1.1 (0.26-4.5)</td>
<td>0.92</td>
<td>7 (0.28)</td>
<td>8 (0.16)</td>
<td>0.36 (0.10-1.49)</td>
</tr>
<tr>
<td>GA</td>
<td>15 (0.60)</td>
<td>39 (0.52)</td>
<td>0.74(0.25-2.2)</td>
<td>0.59</td>
<td>13 (0.52)</td>
<td>26 (0.52)</td>
<td>0.63 (0.2-2.1)</td>
<td>0.44</td>
</tr>
<tr>
<td>AA</td>
<td>6 (0.24)</td>
<td>21 (0.28)</td>
<td>1</td>
<td>--</td>
<td>5 (0.20)</td>
<td>16 (0.32)</td>
<td>1</td>
<td>--</td>
</tr>
<tr>
<td>G/GA</td>
<td>21 (0.84)</td>
<td>54 (0.72)</td>
<td>0.81 (0.29-2.3)</td>
<td>0.56</td>
<td>20 (0.80)</td>
<td>34 (0.68)</td>
<td>0.53 (0.17-1.7)</td>
<td>0.28</td>
</tr>
<tr>
<td>Allele</td>
<td>G</td>
<td>23</td>
<td>69</td>
<td>0.53 (1.9)</td>
<td>0.27</td>
<td>42</td>
<td>62 (0.31-1.2)</td>
<td>0.16</td>
</tr>
<tr>
<td>A</td>
<td>27</td>
<td>81</td>
<td>1</td>
<td>--</td>
<td>23</td>
<td>58</td>
<td>1</td>
<td>--</td>
</tr>
</tbody>
</table>

CI: confidence interval; HCC: Hepatocellular carcinoma in liver cirrhosis; OR: odds ratio; *Patients vs. controls; †Liver cirrhosis/hepatocellular carcinoma (LC/HCC) vs chronic hepatitis.
When comparing allele and genotype frequencies of the IL-10 -1082, no significant differences between the two groups of patients were observed.

Combined effect of IFN-γ (+874T/A) and IL-10 (-1082G/A) gene polymorphisms

Due to the inhibitory action of IL-10 on IFN-γ synthesis, the effect of IFN-γ and IL-10 combined genotypes on chronic hepatitis C genotype 4 outcome was analyzed. Genotypes were grouped into high or low producer genotypes. For IFN-γ: TT and TA genotypes at position +874 were considered as high producer genotypes. AA genotype was considered as a low producer genotype. For IL-10, GG and GA at position -1082 were grouped into high producer genotypes and AA genotype was regarded as a low producer genotype. No statistically significant differences in IFN-γ and IL-10 combined genotype distributions between patients with chronic hepatitis C and Patients with liver cirrhosis and HCC although it increased with disease progression.

Discussion

Host genetic factors have an impact on the clinical outcomes of HCV infection; however, the possible mechanisms remain unclear. The role of immune-pathogenesis in chronic hepatitis C (CHC) leads to extensive exploration of patients’ immunity particularly inflammatory cytokines (Chuang et al., 2009). A shift to Th1-type cytokines has been associated with an exacerbated necro-inflammatory activity and liver fibrosis. Hepatocytes necrosis resulting from chronic inflammation and subsequent regeneration enhances mutagenesis and proto-oncogene stimulation in the host cells, leading to HCC (Bouzgarrou et al., 2009). Cytokine gene single nucleotide polymorphisms (SNPs) are involved in the genesis and progression of HCC (Bei et al., 2014). IFN-γ was found to participate in the immune response involved in fibrogenesis. Several studies provide evidence that IFN-γ has a distinct role in Th1-type cellular response leading to inflammation and liver fibrosis in HCV-related chronic liver disease (Bouzgarrou et al., 2009). Combination of intra-tumoral natural killer cells and IFN-γ was found to be a promising independent predictor for recurrence and survival in HCC (Xiao et al., 2013). Heterogeneity at +874 locus of IFN-γ gene showed no association with response to antiviral therapy with any difference between responders and nonresponders.

In our study, there was no statistically significant differences in IFN-γ (+874T/A) genotype frequency between chronic hepatitis patients genotype 4 and cirrhotic/HCC group although they showed a higher rate of TT, TA, AA and TT+TA polymorphisms.

Findings regarding the associations between IFN-γ (+874T/A) polymorphism and fibrosis in HCV are conflicting. Other studies also showed no significant relationships between IFN-γ +874 A/T allele frequencies and the clinical outcome of HCV infection and fibrosis or liver disease severity (Barrett et al., 2003, Abbas et al., 2005; Gao et al., 2010).

In contrast to our study, Dai et al. (2006) found that T allele of +874 IFN-γ was an independent factor associated with cirrhosis indicating that inheritance of +847 IFN-γ
polymorphism is associated with the cirrhosis in patients with CHC. This could be attributed to our different HCV genotype as 48.7% of their patients had HCV genotype 1b. In addition they did not include HCC to complete the full spectrum of disease progression.

IL-10, whose secretion is regulated by monocytes and lymphocytes, has an important role in the pathogenesis of CHC infection (Helal et al., 2014). It is an anti-inflammatory cytokine and immune response modulator that can influence HCV infection susceptibility as well as spontaneous and treatment-induced viraleradication. Moreover, it has anti-fibrotic properties and plays a role in liver disease progression (Świątek et al., 2012).

In a review that summarized studies on the role of interleukin-10 gene polymorphisms (mainly promoter SNPs at positions -1082(G/A), -819(C/T) and -592(C/A)) regarding susceptibility to HCV infection, course of HCV-related liver disease (fibrrosis, cirrhosis, hepatocellular carcinoma, ALT abnormalities), spontaneous viral clearance and antiviral treatment outcomes; it was found that it is difficult to determine the importance of IL-10 polymorphism as a predictor of clinical outcomes of hepatitis C and response to anti-HCV therapy before its beginning. Thus, they recommended continuation of studies on interleukin-10 polymorphisms and identification of other possible predictive markers in HCV infection that has important practical implications and may contribute to reduce the scale of hepatitis C problem (Świątek et al., 2012).

In our study, no significant difference in the genotype profile of IL-10 (-1082) was detected between chronic HCV (persistent infection) and the spectrum of the increasing severity of liver affection by HCV with liver cirrhosis and HCC. Similarly another study on HCV genotype-4 had the same results as ours (Helal et al., 2014) and other researchers on other genotypes also showed the same results (Kusumoto et al., 2006). Another study by Wu and colleagues from China confirmed the lack of association of IL10 and other gene polymorphisms with HCC recurrence after liver transplantation (Wu et al., 2013).

On the other hand, Knapp et al. (2003) studies revealed an association of the G/G genotype at position 1082 with persistent infection. This association was also confirmed in a study by Vidigal et al. (2002) but this was based on a comparison with healthy controls rather than participants with self-limiting HCV infection. Our study confirms the need of future investigations of host-pathogen interactions underlying the genotype specific clinical outcomes of chronic HCV infection. We have some limitations in our study including low patient number and controls. In conclusion; interferon-γ and interleukin-10 gene polymorphisms are not predictors of disease progression in patients with chronic hepatitis C (Genotype-4).

References


Nermine Ahmed Bahgat et al

virus infection. *Immunogenetics, 55*, 362-9.


